Objective: We evaluated the use of Exenatide in terms of weight reduction and improvement of glycemic control, in patients with type 2 diabetes and obesity from Pakistan. Methodology: The study was done in Shifa International Hospital, Islamabad from year 2013 to 2014. Exenatide was prescribed to 45 patients, in which 19 patients had completed follow-ups. HbA1c, BMI and weight were recorded before and after the treatment. Side effects and reason for early discontinuation were also noted. Results: The concurrent use of Exenatide along with other anti-diabetic medications, enabled patients to reduce an average weight of 6.6kg (average decrease in BMI was 1.82kg/m2) and HbA1c levels of 0.6% over a period of 5 months, making it a promising therapeutic agent in obese and diabetic patients. The most common side effect noted was nausea. Conclusion: Exenatide has a potential to achieve reasonable weight loss and mild improvements in glycemic control in Pakistani obese and diabetic patients.
Exenatide, diabetes mellitus, obesity, GLP-1 agonist